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Biomarkers of axonal degeneration have the potential to improve our capacity to predict and monitor neurological outcome in
multiple sclerosis (MS) patients. Neuroﬁlament proteins, one of the major proteins expressed within neurons and axons, have
been detected in cerebrospinal ﬂuid and blood samples from MS patients and are now being actively investigated for their utility as
prognostic indicators of disease progression in MS. In this paper, we summarize the current literature on neuroﬁlament structure,
assembly, and degeneration and discuss their potential utility as biomarkers for monitoring neurological decline in MS. We also
discuss the need to further develop sensitive methods for assaying neuroﬁlaments in blood to improve clinical applicability.
1.Introduction
MultipleSclerosis(MS)isachronic,debilitatingneurological
disease with an unknown aetiology. The pathology of
this disease is complex and heterogeneous but is typically
characterized by the presence of multifocal demyelinated
plaques, inﬂammation, and axonal injury [1]. The func-
tional consequences of this pathology can include visual
disturbances, fatigue, depression, weakness, numbness, and
cognitive impairment. The earliest symptoms typically begin
in young adulthood [2], a time when the diagnosis of an
unpredictable, chronic neurological disease with signiﬁcant
and often progressive disability is particularly devastating
and unexpected.
Increasingly, axonal injury is recognized as the main
pathological correlate of progressive neurological disabil-
ity in MS [3, 4]. Historically, this axonal damage was
thought to be restricted to chronically demyelinated lesions,
caused by trophic factor deprivation [5] or maladaptive
responses in chronically demyelinated axons [6]. Several
histological and imaging studies have now demonstrated,
however, that axonal damage may also occur in association
with inﬂammation in acute grey and white matter lesions,
and also more diﬀusely in normal-appearing white matter
[7–9].
At present, surrogate markers for axonal damage are not
routinelyusedtomonitordiseaseactivityinMSpatients.The
mostcommonlyuseddiagnosticandmonitoring toolforMS
is magnetic resonance imaging, utilizing T2-weigheted imag-
ing and Gadolinium- (Gd-) enhanced T1-weighted imaging
[10]. These measures, however, lack pathological speciﬁcity,
which is likely to contribute to the poor association between
conventional MRI measures and disability in MS patients
[11, 12]. To address this need, several studies have now
focussed on the detection of neuronal/axonal proteins in
CSF or blood, as biomarkers of axonal degeneration. These
studies are based on the concept that degenerating axons
release their contents into the surrounding extracellular
space, and that some of these axonal components might
be abundant and stable enough to be detectable with
appropriate assays. The detection of such components would
provideaconvenientmeanstoassessthepresenceanddegree
of axonal degeneration in MS, and this information could be
useful for predicting and monitoring the progression of the
disease,andforassessingtheeﬃcacyoftherapeuticstrategies
that are aimed at preventing axonal loss.2 Multiple Sclerosis International
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Figure 1: Diagram of the subunit proteins of neuroﬁlaments. NF-L, NF-M, NF-H, and α-internexin can be regarded as the major subunits
of adult NFs though NFs may also contain peripherin, vimentin, and nestin in certain locations, developmental stages, and possibly damage
or disease states. Phosphorylation sites for protein kinase A (A kinase), protein kinase C (C kinase), and cdc2 kinases (cdc2 kinase) have been
characterized in the globular “head” regions of certain of these molecules as indicated. The regions indicated by KSP, SP, KSD, and DEPPS
are known serine phosphorylation sites in the “tail” regions. EEIIEE, KE repeats, Tail a, E segment, KEP segment, KE segment, RGD, and QE
repeats each refer to speciﬁc kinds of sequence motif. For further details, see Shaw 1998 [13].
2.IntroductiontoNeuroﬁlamentProteins
Neuroﬁlaments (NFs) are the major structural proteins of
neurons. They are most abundant in larger neurons and are
heavily concentrated in axons, in particular long projection
axons. The subunits of NFs belong to the intermediate (IF)
family of proteins, which are characterized by a structurally
conserved α-helical coiled-coil “rod” region which forms the
backbone of the ﬁlament, with variable N and C terminal
extensions (Figure 1) .T h eI Fs u b u n i t so fv e r t e b r a t e sa r e
divided into ﬁve classes based on protein characteristics,
expression pattern, and intron placement. IF subunits Class I
and II include the epithelial keratins; the class III IFs include
vimentin, desmin, and glial ﬁbrillary acidic protein (GFAP),
while the major neuroﬁlament subunits NF-Light (NF-
L), NF-medium (NF-M), NF-Heavy (NF-H), α-internexin,
and nestin form IF class IV. Class V IFs are the lamin
proteins of the nuclear matrix. The expression proﬁle of
Class IV proteins is limited to the nervous system, with
the exception of nestin, which may be found in stem cells
throughout the body. All 5 Class IV genes share a distinct
intron pattern from that seen in other IF genes, indicating a
close evolutionary relationship. The class IV subunits NF-H
and NF-M have unusually long and complex C-terminal
“tail” regions which are responsible for the wispy spacers
seen by electron microscopy and the wider spacing of NFs
comparedtootherIFs.NF-L,NF-M,NF-H,andα-internexin
are all abundant proteins of the nervous systems of adult
mammals, while nestin is expressed early in development
and is normally downregulated in the adult. One class III
IF protein, peripherin, is found copolymerized with NF-L,
NF-M, NF-H, and α-internexin in the NF of some neurons
insigniﬁcantamounts,particularlyintheperipheralnervous
system.Finally,afewapparentlyunusualneuronsintheadult
express another Class III protein, vimentin. Neuroblasts
e x p r e s st h i sp r o t e i n ,b u ti ti sg e n e r a l l yd o w n r e g u l a t e da s
development proceeds. However, in many damage and
disease states, cells will re-express proteins which were
downregulated developmentally, so that expression of any of
the 7 subunits shown in Figure 1 could be associated with
speciﬁc damage or disease states. The various proteins which
may be included in NFs are known to be phosphorylated,Multiple Sclerosis International 3
Table 1: Summary of studies assessing the utility of neuroﬁlaments as biomarkers of axonal damage in patients with multiple sclerosis (MS)
and clinically isolated syndrome (CIS).
Biomarker Fluid Study design Observations Associations with clinical
measures Ref.
NF-L CSF RRMS (n = 6 0 ) ;L Po nt r i a l
initiation and 2yr
78% patients showed ↑ at 0 or 2
yrs. Associated with recent
relapse. No relation with age,
gender, or disease duration.
EDSS
0yr(r2 = 0.27, P<. 05);
2yr(r2 = 0.35, P<. 01)
[16]
NF-L CSF RRMS (n = 41), SPMS (n = 25),
healthy (n = 50)
↑ mean level in all MS subtypes.
Highest during acute relapse. EDSS (ns) [17]
NF-L CSF
CIS (n = 38), RRMS (n = 42),
SPMS (n = 28), PPMS (n = 6);
diagnostic LP
MS/CIS > controls. ↑ NF-L
associated with relapse, T2 lesion
number, Gd enhancing lesions. ↑
in CIS that convert to RRMS.
EDSS (r = 0.192,P<. 05) [18]
NF-L CSF RRMS (n = 16), SP/PP MS
(n = 18) MS > controls EDSS (r = 0.41,P<. 05) [23]
NF-L CSF RRMS (n = 47) MS > controls — [24]
NF-L CSF CDMS (n = 47) MS > controls — [25]
NF-L CSF
RRMS (n = 65), SPMS (n = 10),
PPMS (n = 20); LP on initiation.
Followup at 5 and 14yrs.
↑ NF-L associated with recent
relapse; associated with 3-fold ↑
in risk of developing high MSSS;
more likely to convert from
RRMS to SPMS.
MSSS 14yr (r = 0.3,P<. 01) [26,27]
NF-H CSF
CIS (n = 38), RRMS (n = 92),
SPMS (n = 28), PPMS (n = 6);
diagnostic LP
MS > controls. SP/PPMS >
RRMS. ↑ levels at CIS do not
predict conversion to RRMS. ↑
with relapse. Correlated to age.
EDSS (r = 0.253, P<. 01) [18]
NF-H CSF
RRMS (n = 11), SP/PPMS
(n = 23); LP on trial initiation
and 3yr
SP/PPMS > RRMS. EDSS 3yr (ns trend) [19]
NF-H CSF CIS (n = 52), RRMS (n = 38) CIS > controls. ↑ acute relapse. Correlated with EDSS for CIS
and RRMS. [28]
NF-H Plasma RRMS (n = 30) Median levels RRMS > controls — [20]
Abbreviations:NF-L:neuroﬁlamentlight;NF-H:neuroﬁlamentheavy;CSF:cerebrospinalﬂuid;RRMS:relapsing-remittingMS;SPMS:secondaryprogressive
MS; PPMS: primary progressive MS; CDMS: clinically deﬁnite MS; LP: lumbar puncture; Gd: gadolinium; EDSS: expanded disability status scale; MSSS:
multiple sclerosis severity scale; NS: nonsigniﬁcant; Ref: reference.
glycosylated, and modiﬁed on many sites and contain many
interesting protein sequence motifs, details of which are
discussed in previous publications [13, 14].
Itisnoteworthythatforatypicallargeprojectionneuron,
the volume of the axon may exceed that of the cell body by
a factor of a thousand or more and that NFs can occupy
more than 90% of the axonal cross section. The function
of NFs appears to be to provide axons with mechanical
strength and to control axonal volume. Apparently, in order
to meet these requirements, NF subunits have a very long
half-life and are resistant to endogenous proteases. It is
therefore reasonable to assume that large amounts of NFs,
their subunits, breakdown products, and associated proteins
would be released following axonal loss in MS and in
other damage and disease states, and that their abundance
and stability might make them relatively easy to detect.
There has therefore been much interest in the use of these
proteins as potential biomarkers of damage, disease, and
progression in a variety of neurological states, including MS
[15].
3. Neuroﬁlaments As Biomarkers of
Axonal Degeneration in MS
Several studies have now demonstrated the presence of NF
peptides in the cerebrospinal ﬂuid (CSF) of MS patients
(summarized in Table 1). Most commonly, CSF levels
of these proteins have been assessed using enzyme-linked
immunosorbent assays (ELISAs) [16–20]; however, Western
blotting and dot blotting have also been utilized on occasion
[21–23].
3.1. NF-L. The potential use of the NF protein subunits as
surrogate markers of axonal degeneration in MS was ﬁrst
explored by Lycke et al. [16], who developed an NF-L ELISA
in house using an aﬃnity puriﬁed chicken NF-L antibody.
In this study, CSF levels of NF-L protein were measured in
60 patients with clinically deﬁnite relapsing-remitting MS
(RR-MS). The CSF samples were collected from patients
on initiation of the trial, and then 2 years later. It was4 Multiple Sclerosis International
demonstrated that CSF NF-L levels were increased on at
least one occasion in 78% of cases, and that these levels
were moderately associated with disability. Levels of NF-L
were also found to be higher in patients who had suﬀered
a relapse within 3 months of sampling, indicating a temporal
correlation between acute inﬂammatory activity and neu-
rodegeneration in this disease. An interesting observation to
arise from this study was that sequential CSF NF-L samples
were not persistently elevated in all patients, highlighting the
dynamic nature of MS-associated axonal degeneration.
Increases in intrathecal NF-L were subsequently con-
ﬁrmed by several groups, for both RR-MS and progressive
MS cases [17, 23–25]. In accordance with original observa-
t i o n sm a d eb y L y k ee ta l .[ 16], a small prospective study of
13 RR-MS patients with recent relapse conﬁrmed that NF-L
levels peak during acute relapse and decline within 3 months
[17]. In this same study, CSF NF-L levels were also assessed
in a larger group of 66 patients with clinically deﬁnite
MS for associations with disability as assessed by expanded
disability status scale (EDSS) and neurologic symptoms. The
level of NF-L in CSF was not found to be associated with
neurological disability outcome measures.
In a more recent set of retrospective studies, NF-L levels
were measured from CSF samples collected at diagnostic
lumbar puncture in 99 patients with clinically deﬁnite MS,
to evaluate whether NF-L levels at diagnosis could be used
to predict more rapidly progressing disease. Of these, 94
patientshadcomprehensiveclinicaldataavailabletoconduct
association studies between CSF NF-L levels at diagnosis,
and disease severity at 5 years [26]a n d1 4y e a r s[ 27].
It was found that elevated NF-L levels were associated with
a 3-fold increase in the risk of developing severe MS, as
estimated by bivariate and multivariate logistic regression
analysis, particularly among cases with RR-MS and cases
with a recent relapse. Further, approximately 60% of patients
withhighCSFNF-Llevels(>386ng/mL)convertedfromRR-
MS to secondary progressive MS (SP-MS) within the 14-year
followup period compared to 30% of patients with moderate
or low levels (<386ng/mL). These studies suggest that
high CSF NF-L levels, assessed in early MS, are potentially
predictive of more rapid disease progression over time. High
NF-L levels in early MS may also be useful for predicting
conversion to progressive disease. In accordance with these
studies, it has also been reported that CSF NF-L levels are
higher, on average, in clinically isolated syndrome (CIS)
cases that convert to RR-MS within 3 years compared to
nonconverters [18]. Collectively, this recent work supports
theuseofNF-LCSFlevelsasaprognosticindicatorofdisease
course in MS patients.
3.2. NF-H. The high-molecular-weight NF subunit, NF-H,
has also been a focus of biomarker studies. Compared with
assessments of CSF NF-L levels, however, fewer studies
have been conducted to evaluate NF-H as a biomarker
of neurodegeneration in MS. The axonal form of NF-H
is heavily phosphorylated [21], is resistant to proteolysis
[29], and is very immunogenic, which allows it to be sensi-
tively detected using appropriate immunological assays [30].
The phosphorylated region of this axonal form of NF-H
(here referred to as pNF-H) is also very unusual, comprising
∼50 tandem repeat lysine-serine-proline (KSP) containing
peptides, the serine of each being a phosphorylation site
[13, 31]. These unusual properties make pNF-H an ideal
target for immunological detection, since it is stable upon
release from neurons and can be captured and detected
with exceptionally high avidity due to its exotic multiepitope
nature. Since pNF-H is only found in axons, its detection in
CSF, blood or other bodily ﬂuids points unambiguously to
release of this protein from axons.
The ﬁrst ELISA method described for NF-H made use of
the commercial SMI35 monoclonal antibody in the capture
role [32]. SMI35, available from Covance (Princeton, NJ)
is speciﬁc for the axonal, heavily phosphorylated form of
NF-H, namely pNF-H. This ELISA was subsequently utilized
in a 3-year followup study conducted to evaluate CSF levels
of pNF-H in RR-MS and progressive MS cases. In contrast to
observations for NF-L, the median pNF-H levels were found
to be highest for patients with progressive disease [19]. There
was also some evidence to support an association between
pNF-H level and EDSS at followup, and also a potential
propensity for patients with high pNF-H levels at baseline
to exhibit progression in disease EDSS at followup. These
analyses did not, however, reach statistical signiﬁcance, most
likely due to the limited sample size. In support of these
observations, CSF pNF-H levels were shown to be weakly
associated with EDSS (R = 0.253, P<. 009) in a larger
cohort of patients comprising CIS (n = 38), RR-MS (n =
42), SP-MS (n = 28), and primary progressive MS (PP-MS,
n = 6) cases [18]. In this study, the average CSF pNF-H
levels were higher in patients with all subtypes of MS relative
to samples taken from controls. Interestingly, CSF pNF-H
levels were, on average, 1.5-fold higher for SP-MS and PP-
MS cases relative to RR-MS cases. Further, in contrast to
observations for NF-L, levels of CSF pNF-H in CIS cases
did not predict conversion to clinically deﬁnite MS. These
studies suggest the pNF-H may be more useful as a measure
of ongoing neurodegenerative activity in MS patients, which
would make this protein a potential candidate for use as
a surrogate marker for assessment of treatments aimed at
reducing axonal injury. A retrospective study of 30 patients
has already been conducted to determine whether plasma
pNF-H levels could be used to measure responsiveness to
interferon-β treatment. Although it was found that plasma
pNF-H levels tended to be higher in patients who did not
respond well to Interferon-β treatment, this did not reach
statistical signiﬁcance, possibly due to the small sample size.
Hence, additional studies are required to assess the utility of
blood or CSF pNF-H levels as an indicator of disease activity
and, potentially, therapeutic eﬃcacy.
3.3. NF-M and α-Internexin. The other major neuroﬁlament
subunits of the mature nervous system, NF-M and α-
internexin, are presumably, like NF-L and NF-H, released
during axonal degradation. Some evidence suggests that
α-internexin is a particularly unstable protein, diﬃcult to
isolate biochemically because it is readily degraded [33], andMultiple Sclerosis International 5
therefore the intact form of this protein is unlikely to be a
suitable biomarker. On the other hand, the NF-M appears to
be intermediate in resistance to proteases compared to NF-L
and NF-H but has not, to date, been studied as a potential
biomarker [34].
4. AxonalInjuryBiomarker Panels Utilising
Neuroﬁlament Proteins
Theuseofmultipleaxonalinjurybiomarkersincombination
panels in CSF has been explored as a method to gain
additional power to explore disease prognosis and activity.
The premise behind these studies is that individual axonal
biomarkers may only reﬂect particular aspects of disease
activity or may be released at diﬀerent stages in the degen-
erative process and are therefore likely to be less informative
in isolation than in combination.
Studies by Brettschneider et al. [28] measured CSF levels
of the axonal cytoskeletal proteins microtubule-associated
protein tau and pNF-H in the same MS patients to ascertain
whether this could improve the sensitivity of predicting
disability progression relative to conventional MRI methods.
Interestingly, when utilized alone, changes in CSF pNF-H
or tau levels did not increase the sensitivity for predicting
conversion to clinically deﬁnite MS in patients with CIS at
48-month followup. However, by testing CSF for either tau
or pNF-H, it was possible to improve the sensitivity and
speciﬁcity of these biomarkers relative to MRI. Interestingly,
higher CSF levels of pNF-H, but not tau, were found to
be associated with higher EDSS in both CIS and RR-MS,
which may indicate that NF-H proteins are more sensitive
indicators of axonal damage that is associated with physically
disabling symptoms of MS.
Teunissen et al. [18] have also evaluated the utility of
combinations of axonal biomarkers for monitoring disease
activity in MS patients. In their study, levels of neuron-
speciﬁc amino acid n-acetyl aspartate (NAA), NF-L, pNF-
H, and tau were measured in the same CSF samples and
were then assessed for associations with disease subtype,
disability,andMRIoutcomemeasures.Eachoftheseproteins
showed speciﬁc patterns of change over the course of the
disease, with the highest average NF-L levels observed in
RR-MS patients. Conversely, average NAA and pNF-H levels
were highest in patients with progressive disease. Levels of
tau were not signiﬁcantly changed between the groups. It
was proposed that these diﬀerences could reﬂect variability
in the dynamics of release for these axonal proteins during
degenerative processes. However, both of these observations
need validation in independent cohorts.
5. Neuroﬁlament ProteinSubunitsAs Blood
Biomarkers of Axonal Degeneration in MS
Despite these promising observations, the clinical utility
of CSF biomarkers is limited by the lack of acceptability,
invasiveness, and risks posed by repeated lumbar puncture.
Hence, blood biomarkers of axonal degeneration could
provide a major advance in the paraclinical monitoring of
disease activity in MS. The development of methods for
measuring biomarkers in serum is, however, complicated
by the potential inﬂuence of the blood brain barrier on
the dynamics of release of these proteins into blood and
the much higher protein concentration and complexity of
blood as compared to CSF. In addition, proteins released
into blood may be subjected to proteolysis and may bind
to blood components that are actively cleared from the
blood. However, blood brain barrier compromise appears
to be an early feature of the MS disease process [35], and
presumably, potential axonal biomarker proteins released
intotheextracellularspaceinlesionswouldhavereadyaccess
into blood from sites of active MS pathology. Such proteins
could then be detected with assays of suﬃcient aﬃnity and
avidity to work eﬀectively in the concentrated and complex
protein context of blood, plasma, and serum.
Relativelyfewstudieshaveevaluatedbloodbiomarkersas
potential measures of neurodegeneration in MS. Thus far, a
suitable method for detecting NF-L in blood has not been
identiﬁed. The pNF-H protein, however, has been detected
in blood samples, using two independently developed ELISA
methods. The SMI35-based pNF-H ELISA was used to show
that in a small group of 30 RR-MS patients, median plasma
pNF-H levels were elevated relative to healthy controls [20].
This same method was used to demonstrate that in patients
with acute optic neuritis, elevated plasma NF-H levels were
associated with poor recovery of visual acuity and were also
inversely correlated with visual acuity at presentation [36].
One of the present authors (G. Shaw) has also pub-
lished a pNF-H assay which used an aﬃnity puriﬁed
chicken polyclonal antibody in that capture role (Cα-pNF-
H ELISA) [37], which has become commercially available
from EnCor Biotechnology Inc. (Gainesville, FL), from
BioVendor (Modrice, Czech Republic) and from Millipore
(Billerica, MA). This assay has been used on a set of human
CSF samples which included MS samples and shown to
produce signals very similar to the SMI35-based assay [38].
A second generation pNF-H assay, using a novel monoclonal
pNF-H capture antibody screened originally by ability to
capture pNF-H from concentrated protein solutions, has
also been described and is marketed by EnCor Biotech-
nology (Mα-pNF-H ELISA) [39]. These ELISA methods
have been used to measure pNF-H in serum in several
neurological conditions including aneurysmal subarachnoid
haemorrhage [40], amyotrophic lateral sclerosis [39], Leber’s
hereditary optic neuropathy [41], and neonatal hypoxic-
ischemic encephalopathy [42, 43], but no publication has
as yet described the use of this assay on plasma or serum
samples from MS patients.
We have shown, however, that the Cα-pNF-H ELISA is
a powerful serum marker of spinal cord axon loss in mice
with experimental autoimmune encephalomyelitis (EAE),
an experimental model of MS. In this model, serum pNF-
H levels are associated with axonal loss (r =− 0.80, P<
.001) and disability (r = 0.75, P<. 001), providing
evidence that serum pNF-H levels accurately measure axon
loss during inﬂammatory neurodegenerative changes in the
CNS [44]. Interestingly, a drug known to ameliorate the
EAE phenotype in these mice also greatly reduced the blood6 Multiple Sclerosis International
pNF-H levels. This suggests that serum pNF-H levels might
be used in animal models to discover novel MS drugs and,
if established in humans, to monitor the eﬀectiveness of
therapies in MS patients. In preliminary studies, we have
also used the Mα-pNF-H ELISA to show that serum pNF-
H levels are elevated in around 10% of RRMS patients
who show more rapidly progressing disease, suggesting
that previously reported changes in CSF pNF-H levels in
association with disease progression in MS could also be
reﬂected in serum. Importantly, we have also been able to
conﬁrm the presence of NF-H peptides in these samples
by MALDI-TOF mass spectrometry methodology, further
validatingthelikelyspeciﬁcityofthisELISAmethodologyfor
detecting NF-H peptides [45].
6. Conclusion
The detection of NF subunits holds considerable promise as
a means to monitor axonal loss in in MS patients. Work is
being focused on the development of yet more speciﬁc and
sensitive assays for NF proteins of utility both in CSF and
blood. It will also be important to understand how these
proteins are released from axons degenerating as a result
of the MS disease process. While pNF-H released into the
CSF of aneurysmal subarachnoid hemorrhage patients is
mostly intact and unproteolyzed [40], we do not currently
know what form is present in the blood of these patients,
or in fact, any other group of patients. This raises the
interesting possibility that NF subunits that are released with
damage may be processed in disease-speciﬁc ways, and that
these products might be detectable with reﬁned assays of
appropriate speciﬁcity. If this is correct, it may eventually
b ep o s s i b l et od e t e c ta x o n a ll o s ss p e c i ﬁ c a l l yd u et ot h e
MS disease process. Future studies should therefore aim to
develop more sensitive methods for measuring the various
NF subunits in CSF, plasma, or serum to ascertain whether
these biomarkers will be useful in the clinic for predicting
MS onset, and for monitoring MS progression and response
to therapy.
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G. Shaw holds equity in EnCor Biotechnology Inc., a com-
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receiving royalties or equity growth.
References
[1] C. Lucchinetti, W. Br¨ u c k ,J .P a r i s i ,B .S c h e i t h a u e r ,M .
Rodriguez, and H. Lassmann, “Heterogeneity of multiple
sclerosis lesions: implications for the pathogenesis of demyeli-
nation,” Annals of Neurology, vol. 47, no. 6, pp. 707–717, 2000.
[2] C. Confavreux and S. Vukusic, “Natural history of multiple
sclerosis: a unifying concept,” Brain, vol. 129, no. 3, pp. 606–
616, 2006.
[3] C. Bjartmar and B. D. Trapp, “Axonal and neuronal degen-
eration in multiple sclerosis: mechanisms and functional
consequences,” Current Opinion in Neurology, vol. 14, no. 3,
pp. 271–278, 2001.
[4] S. G. Waxman, “Demyelinating disease—new pathological
insights, new therapeutic targets,” New England Journal of
Medicine, vol. 338, no. 5, pp. 323–325, 1998.
[5] A. Compston, “Remyelination of the central nervous system,”
Multiple Sclerosis, vol. 1, no. 6, pp. 388–392, 1996.
[ 6 ]M .J .C r a n e r ,J .N e w c o m b e ,J .A .B l a c k ,C .H a r t l e ,M .
L. Cuzner, and S. G. Waxman, “Multiple sclerosis: altered
axonal expression of NaV1.2 and NaV1.6 sodium channel and
Na
+/Ca
2+ exchanger,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 101, no. 21, pp.
8168–8173, 2004.
[7] J. W. Peterson, L. B¨ o, S. M¨ ork, A. Chang, and B. D.
Trapp, “Transected neurites, apoptotic neurons, and reduced
inﬂammation in cortical multiple sclerosis lesions,” Annals of
Neurology, vol. 50, no. 3, pp. 389–400, 2001.
[8] B. D. Trapp, J. Peterson, R. M. Ransohoﬀ, R. Rudick, S. M¨ ork,
and L. B¨ o, “Axonal transection in the lesions of multiple
sclerosis,” New England Journal of Medicine, vol. 338, no. 5, pp.
278–285, 1998.
[9] A.Kutzelnigg,C.F.Lucchinetti,C.Stadelmannetal.,“Cortical
demyelination and diﬀuse white matter injury in multiple
sclerosis,” Brain, vol. 128, no. 11, pp. 2705–2712, 2005.
[10] M. A. Sahraian and A. Eshaghi, “Role of MRI in diagnosis
and treatment of multiple sclerosis,” Clinical Neurology and
Neurosurgery, vol. 112, no. 7, pp. 609–615, 2010.
[11] R. Zivadinov and T. P. Leist, “Clinical-magnetic resonance
imaging correlations in multiple sclerosis,” Journal of Neu-
roimaging, vol. 15, no. 4, pp. 10S–21S, 2005.
[ 1 2 ]D .H .M i l l e r ,R .I .G r o s s m a n ,S .C .R e i n g o l d ,a n dH .F .
McFarland, “The role of magnetic resonance techniques in
understanding and managing multiple sclerosis,” Brain, vol.
121, no. 1, pp. 3–24, 1998.
[13] G. Shaw, Neuroﬁlaments. Biotechnology Intelligence Unit,
Springer, New York, NY, USA, 1998.
[14] R. Perrot, R. Berges, A. Bocquet, and J. Eyer, “Review of the
multipleaspectsofneuroﬁlamentfunctions,andtheirpossible
contribution to neurodegeneration,” Molecular Neurobiology,
vol. 38, no. 1, pp. 27–65, 2008.
[15] A. Petzold, “Neuroﬁlament phosphoforms: surrogate markers
for axonal injury, degeneration and loss,” Journal of the
Neurological Sciences, vol. 233, no. 1-2, pp. 183–198, 2005.
[16] J. N. Lycke, J. E. Karlsson, O. Andersen, and L. E. Rosengren,
“Neuroﬁlament protein in cerebrospinal ﬂuid: a potential
marker of activity in multiple sclerosis,” Journal of Neurology
Neurosurgery and Psychiatry, vol. 64, no. 3, pp. 402–404, 1998.
[17] C. Malmestr¨ om, S. Haghighi, L. Rosengren, O. Andersen, and
J.Lycke, “Neuroﬁlamentlightproteinandglialﬁbrillaryacidic
protein as biological markers in MS,” Neurology, vol. 61, no.
12, pp. 1720–1725, 2003.
[18] C. E. Teunissen, E. Iacobaeus, M. Khademi et al., “Combina-
tion of CSF N-acetylaspartate and neuroﬁlaments in multiple
sclerosis,” Neurology, vol. 72, no. 15, pp. 1322–1329, 2009.
[19] A. Petzold, M. J. Eikelenboom, G. Keir et al., “Axonal damage
accumulates in the progressive phase of multiple sclerosis:
three year follow up study,” Journal of Neurology, Neurosurgery
and Psychiatry, vol. 76, no. 2, pp. 206–211, 2005.
[20] A. Petzold, D. Brassat, P. Mas et al., “Treatment response
in relation to inﬂammatory and axonal surrogate marker in
multiple sclerosis,” Multiple Sclerosis, vol. 10, no. 3, pp. 281–
283, 2004.
[21] L. A. Sternberger and N. H. Sternberger, “Monoclonal anti-
bodies distinguish phosphorylated and nonphosphorylatedMultiple Sclerosis International 7
forms of neuroﬁlaments in situ,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 80, no.
19, pp. 6126–6130, 1983.
[22] M. E. Goldstein, L. A. Sternberger, and N. H. Sternberger,
“Varying degrees of phosphorylation determine microhetero-
geneity of the heavy neuroﬁlament polypeptide (Nf-H),”
Journal of Neuroimmunology, vol. 14, no. 2, pp. 135–148, 1987.
[23] Y. K. Semra, O. A. Seidi, and M. K. Sharief, “Heightened
intrathecal release of axonal cytoskeletal proteins in multiple
sclerosis is associated with progressive disease and clinical
disability,” Journal of Neuroimmunology, vol. 122, no. 1-2, pp.
132–139, 2002.
[24] N. Norgren, L. Rosengren, and T. Stigbrand, “Elevated
neuroﬁlament levels in neurological diseases,” Brain Research,
vol. 987, no. 1, pp. 25–31, 2003.
[25] S. Haghighi, O. Andersen, A. Od´ en, and L. Rosengren,
“Cerebrospinal ﬂuid markers in MS patients and their healthy
siblings,” Acta Neurologica Scandinavica, vol. 109, no. 2, pp.
97–99, 2004.
[26] N. Norgren, P. Sundstr¨ om, A. Svenningsson, L. Rosengren,
T. Stigbrand, and M. Gunnarsson, “Neuroﬁlament and glial
ﬁbrillary acidic protein in multiple sclerosis,” Neurology, vol.
63, no. 9, pp. 1586–1590, 2004.
[27] J. Salzer, A. Svenningsson, and P. Sundstr¨ om, “Neuroﬁlament
light as a prognostic marker in multiple sclerosis,” Multiple
Sclerosis, vol. 16, no. 3, pp. 287–292, 2010.
[28] J. Brettschneider, A. Petzold, A. Junker, and H. Tumani,
“Axonal damage markers in the cerebrospinal ﬂuid of patients
with clinically isolated syndrome improve predicting conver-
sion to deﬁnite multiple sclerosis,” Multiple Sclerosis, vol. 12,
no. 2, pp. 143–148, 2006.
[29] H. C. Pant, “Dephosphorylation of neuroﬁlament proteins
enhances their susceptibility to degradation by calpain,”
Biochemical Journal, vol. 256, no. 2, pp. 665–668, 1988.
[ 3 0 ]M .J .C a r d e n ,W .W .S c h l a e p f e r ,a n dV .M .Y .L e e ,“ T h e
structure, biochemical properties, and immunogenicity of
neuroﬁlament peripheral regions are determined by phospho-
rylation state,” Journal of Biological Chemistry, vol. 260, no. 17,
pp. 9805–9817, 1985.
[31] P. Grant and H. C. Pant, “Neuroﬁlament protein synthesis and
phosphorylation,” Journal of Neurocytology, vol. 29, no. 11-12,
pp. 843–872, 2000.
[32] A. Petzold, G. Keir, A. J. E. Green, G. Giovannoni, and E. J.
Thompson, “A speciﬁc ELISA for measuring neuroﬁlament
heavy chain phosphoforms,” Journal of Immunological Meth-
ods, vol. 278, no. 1-2, pp. 179–190, 2003.
[33] F. C. Chiu, E. A. Barnes, K. Das et al., “Characterization of a
novel 66 kd subunit of mammalian neuroﬁlaments,” Neuron,
vol. 2, no. 5, pp. 1435–1445, 1989.
[34] G. Shaw, C. Yang, L. Zhang, P. Cook, B. Pike, and W. D. Hill,
“Characterization of the bovine neuroﬁlament NF-M protein
and cDNA sequence, and identiﬁcation of in vitro and in vivo
calpain cleavage sites,” Biochemical and Biophysical Research
Communications, vol. 325, no. 2, pp. 619–625, 2004.
[35] A. G. Kermode, A. J. Thompson, P. Tofts et al., “Breakdown
of the blood-brain barrier precedes symptoms and other MRI
signs of new lesions in multiple sclerosis. Pathogenic and
clinical implications,” Brain, vol. 113, no. 5, pp. 1477–1489,
1990.
[ 3 6 ]A .P e t z o l d ,K .R e j d a k ,a n dG .T .P l a n t ,“ A x o n a ld e g e n a r a t i o n
and inﬂammation in acute optic neuritis,” Journal of Neurol-
ogy,NeurosurgeryandPsychiatry,vol.75,no.8,pp.1178–1180,
2004.
[37] G. Shaw, C. Yang, R. Ellis et al., “Hyperphosphorylated neu-
roﬁlament NF-H is a serum biomarker of axonal injury,”
Biochemical and Biophysical Research Communications, vol.
336, no. 4, pp. 1268–1277, 2005.
[38] A. Petzold and G. Shaw, “Comparison of two ELISA methods
for measuring levels of the phosphorylated neuroﬁlament
heavy chain,” Journal of Immunological Methods, vol. 319, no.
1-2, pp. 34–40, 2007.
[39] K. Boylan, C. Yang, J. Crook et al., “Immunoreactivity of the
phosphorylated axonal neuroﬁlament H subunit (pNF-H) in
blood of ALS model rodents and ALS patients: evaluation
of blood pNF-H as a potential ALS biomarker,” Journal of
Neurochemistry, vol. 111, no. 5, pp. 1182–1191, 2009.
[40] S. B. Lewis, R. A. Wolper, L. Miralia, C. Yang, and G. Shaw,
“Detection of phosphorylated NF-H in the cerebrospinal ﬂuid
and blood of aneurysmal subarachnoid hemorrhage patients,”
Journal of Cerebral Blood Flow and Metabolism,v o l .2 8 ,n o .6 ,
pp. 1261–1271, 2008.
[41] J. Guy, G. Shaw, F. N. Ross-Cisneros et al., “Phosphorylated
neuroﬁlament heavy chain is a marker of neurodegeneration
in Leber Hereditary Optic Neuropathy (LHON),” Molecular
Vision, vol. 14, pp. 2443–2450, 2008.
[42] M. Douglas-Escobar, C. Yang, J. Bennett et al., “A pilot
study of novel biomarkers in neonates with hypoxic-ischemic
encephalopathy,” Pediatric Research, vol. 68, no. 6, pp. 531–
536, 2010.
[43] N. C. Ringger, S. Giguere, P. Morresey et al., “Biomarkers of
brain injury in foals with hypoxic-ischemic encephalopathy,”
Journal of Veterinary Internal Medicine, vol. 25, no. 1, pp. 132–
137, 2011.
[44] M. M. Gresle, G. Shaw, B. Jarrott et al., “Validation of a novel
biomarker for acute axonal injury in experimental autoim-
mune encephalomyelitis,” Journal of Neuroscience Research,
vol. 86, no. 16, pp. 3548–3555, 2008.
[45] M. M. Gresle, G. Shaw, Y. Liu et al., “Validation of phos-
phorylated neuroﬁlament H as a serum biomarker of neu-
rodegeneration in multiple sclerosis,” in European Committee
for Treatment and Research in Multiple Sclerosis, Gothenburg,
Sweden, 2010.